• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Phastar Appoints Chris Schoonmaker as Chief Operations Officer

    Charles River Labs Opens Plasmid DNA CoE in Cheshire, UK

    EQT Private Equity Acquires SPT Labtech from Battery Ventures

    Shimadzu Scientific Instruments Extends HQ Campus

    Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Shimadzu Scientific Instruments Extends HQ Campus

    Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills

    Batavia Enters Commercial Manufacturing Business

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Charles River Labs Opens Plasmid DNA CoE in Cheshire, UK

    EQT Private Equity Acquires SPT Labtech from Battery Ventures

    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    MasterControl and Elemental Machines Form Biomanufacturing Partnership

    Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    CMC Pharmaceuticals

    Vector Partners Limited

    Quotient Sciences

    Biosynth Carbosynth
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    CMC Pharmaceuticals

    Vector Partners Limited

    Quotient Sciences

    Biosynth Carbosynth
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    Novartis

    ...

    Novartis
    Related CONTENT
    • Coriolis Pharma
    • Mogene
    • Softweb Solutions
    • Vetio Animal Health
    • Top 25 Pharma and Biopharma Companies
    07.15.19
    Headquarters: Basel, Switzerland
    twitter.com/novartis
    www.novartis.com



    Headcount: 125,161
    Year Established: 1996
    Revenues:  $51,900  (+6%)
    Pharma Revenues:  $44,751  (+6%)
    Net Income:  $12,614  (+64%)
    R&D:  $9,074  (+1%)

    TOP SELLING DRUGS
    Drug Indication 2018 Sales (+/-%)
    Gilenya autoimmune disease $3,341 5%
    Cosentyx  Psoriasis, ankylosing spondylitis and psoriatic arthritis $2,837 37%
    Lucentis age-related macular degeneration $2,046 8%
    Tasigna chronic myeloid leukemia $1,874 2%
    Sandostatin acromegaly $1,587 -2%
    Gleevec Leukaemia, chronic myeloid (CML) $1,561 -20%
    Afinitor oncology $1,556 2%
    Galvus diabetes $1,284 4%
    Promacta Thrombocytopaenic purpura, idiopathic (ITP) $1,174 35%
    Tafinlar Melanoma $1,155 32%

    With pharmaceutical sales of nearly $45 billion, Novartis slid into second just ahead of Roche in this year’s report—up four spots from last year’s sixth place ranking. Under the leadership of new chief executive, Vasant Narshimhan, 2018 saw Novartis involved in several deals that has the Swiss pharma giant focused more on medicines. 

    First it inked an $8.7 billion deal to acquire gene therapy company AveXis as part of its neuroscience strategy. AveXis is conducting several clinical studies for the treatment of spinal muscular atrophy, or SMA, an inherited neurodegenerative disease caused by a defect in a single gene. Their gene therapy candidate AVXS-101 has the potential to be the first one-time gene replacement therapy for SMA according to Novartis, and it currently has orphan drug designation from the U.S. Food and Drug Administration for the treatment of SMA.

    The deal followed shortly after Novartis sold its stake in its consumer health-care joint venture to GlaxoSmithKline for $13 billion. The company also decided to spin off its Alcon eye-care unit and sold parts of its Sandoz generic-drugs unit, specifically the Sandoz U.S. dermatology business and generic U.S. oral solids portfolio, to Aurobindo Pharma USA for $800 million.

    The Sandoz U.S. portfolios to be sold to Aurobindo include approximately 300 products as well as additional development projects. The sale includes the Sandoz U.S. generic and branded dermatology businesses as well as its dermatology development center. As part of the transaction, Aurobindo will acquire the manufacturing facilities in Wilson, NC, and in Hicksville and Melville, NY.

    In another acquisition, Novartis bought cancer-drug maker Endocyte for $2.1 billion. Endocyte is a U.S. company developing a new treatment for prostate cancer. It specializes in radiopharmaceuticals, a new class of drug that carries radioactive substances directly to cancer cells so they can kill tumor cells at close range. It uses drug conjugation technology to develop targeted therapies with companion imaging agents, including 177Lu-PSMA-617, a potential first-in-class investigational radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

    The prostate cancer drug bolsters its capability in the field, which it expects to be a key growth driver moving forward, and joins another late-stage radiopharmaceutical directed at a rare form of gut cancer, acquired when it bought Advanced Accelerator Applications S.A. for $3.9 billion at the end of 2017.

    Expanding manufacturing capacity
    At the end of 2018, Novartis announced it had made an offer for the French contract development and manufacturing organization (CDMO), CellforCure, from its parent, LFB. CellforCure is one of the first and largest CDMOs producing cell and gene therapies in Europe.

    The deal has subsequently closed for an undisclosed amount and includes the cell and gene manufacturing facility located in Les Ulis, France. CellforCure is now a wholly owned Novartis manufacturing site, joining the network of cell and gene therapy sites including Morris Plains, NJ in the U.S. and Stein, Switzerland, where construction continues to progress on the €79 million facility.
    The deal builds on a previously signed agreement in July 2018. Novartis signed a deal with CellforCure to produce CAR-T cell therapies including Kymriah (tisagenlecleucel), the first CAR-T cell therapy approved by the U.S. Food and Drug Administration (FDA) and indicated for two distinct, difficult-to-treat cancers in the U.S., EU, Switzerland, Canada and Australia. Novartis and CellforCure have successfully completed technology transfer and Kymriah clinical supply production is expected to begin by mid-2019.

    In addition to the CellforCure deal, Novartis has made several steps to strengthen and expand its cell and gene manufacturing, including signing a strategic licensing, collaboration and share purchase agreement with Cellular Biomedicine Group (CBMG) to manufacture and supply Kymriah in China; expanding an alliance with the Fraunhofer Institute in Germany to support manufacturing for clinical trials and post approval manufacturing; and a contract manufacturing collaboration in Japan.

    Partnership for virtual trials
    Novartis formed an alliance with Science 37 to initiate up to 10 new clinical trials over the next three years. The studies will blend virtual and traditional models, with increasing degrees of decentralization towards a mostly “site-less” model. Novartis was an early investor in Science 37 and together have already initiated virtual trials for cluster headache, acne and nonalcoholic steatohepatitis (NASH).

    The new decentralized trials in the U.S. will focus on dermatology, neuroscience and oncology, leveraging Science 37’s proprietary Network Oriented Research Assistant (NORA) technology, which enables patients to participate in studies using mobile devices and telemedicine services. Through this alliance, the companies plan to apply Science 37’s customized enterprise software to some of the leading clinical development programs of Novartis.

    According to the Center for Information & Study on Clinical Research Participation (CISCRP), only 2% of the eligible population in the U.S. participate in clinical trials. Those who do participate attend an average of 11 trial site visits in six months, representing a significant burden for both patients and trial centers. By bringing the trial to the patient, Novartis aims to decrease the burden of clinical trial participation on patients and trial centers. 
    Related Searches
    • cancer
    • canada
    • fda
    • acquisition
    Suggested For You
    Coriolis Pharma Coriolis Pharma
    Mogene Mogene
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Top 25 Pharma and Biopharma Companies Top 25 Pharma and Biopharma Companies
    Pistoia Alliance, backed by Roche, AZ and Bayer, to Introduce FAIR Project Pistoia Alliance, backed by Roche, AZ and Bayer, to Introduce FAIR Project
    Top 25 Pharma and Biopharma Companies Top 25 Pharma and Biopharma Companies
    Roche Roche
    The Top Companies Report The Top Companies Report
    11	Bristol-Myers Squibb 11 Bristol-Myers Squibb
    FLAMMA Acquires Teva’s Philadelphia cGMP Facility FLAMMA Acquires Teva’s Philadelphia cGMP Facility
    Celldex Therapeutics Appoints CMO Celldex Therapeutics Appoints CMO
    Japan First to Approve Roche’s Rozlytrek Japan First to Approve Roche’s Rozlytrek
    The Orphan Promise The Orphan Promise
    FDA Approves Roche’s Venclexta for CLL FDA Approves Roche’s Venclexta for CLL

    Related Content

    • Coriolis Pharma

      Coriolis Pharma

      ...
      Daniel Weinbuch, Dr. 07.01.21

    • Mogene

      ...
      Craig Morley, CEO 11.17.20

    • Softweb Solutions

      ...
      Micheal Jury, Marketing Manager 09.23.20


    • Vetio Animal Health

      Vetio Animal Health

      ...
      John Kane, CEO 10.24.19

    • Top 25 Pharma and Biopharma Companies

      Top 25 Pharma and Biopharma Companies

      (Based on 2018 Pharma/Biopharma Sales, in $U.S. Millions)
      Tim Wright & Kristin Brooks 07.18.19

      Loading, Please Wait..
      Trending
      • Regulatory Report: Analytical Procedure Development
      • Pierre Fabre And Lonza Enter Manufacturing Agreement
      • Pfizer, BioNTech Adapt COVID Vax Against Omicron
      • Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills
      • Shimadzu Scientific Instruments Extends HQ Campus
      Breaking News
      • Phastar Appoints Chris Schoonmaker as Chief Operations Officer
      • Charles River Labs Opens Plasmid DNA CoE in Cheshire, UK
      • EQT Private Equity Acquires SPT Labtech from Battery Ventures
      • Shimadzu Scientific Instruments Extends HQ Campus
      • Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills
      View Breaking News >
      CURRENT ISSUE

      June 2022

      • Newsmakers: Darren Shirley
      • Are You Prepared for the 2023 DSCSA Deadline?
      • Rethinking the Changing Role of the CRO
      • 23rd Annual Salary Survey
      • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
      • CEO Spotlight: David Chang
      • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
      • CRO Industry Market Report

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Kensing Acquires Vitae Naturals
      CoQ10 and Royal Jelly Supplementation May Improve High Intensity Exercise
      Shiitake Mushroom Extract Appears Helpful in HPV Infections
      Coatings World

      Latest Breaking News From Coatings World

      Sheboygan Paint Company Adds Rosey Malchow as Customer Experience Manager
      PPG to Announce Second Quarter 2022 Results July 21
      Evonik Unveils Range of Sustainable Liquid Polybutadienes
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Researchers Develop New Apparatus for the Treatment of Cardiovascular Diseases
      NovaXS Unveils New Prototype of Needle-Free Injection Therapy Smart Medical Device
      Meddux Opens New Facility in Boulder, Colorado
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Phastar Appoints Chris Schoonmaker as Chief Operations Officer
      Charles River Labs Opens Plasmid DNA CoE in Cheshire, UK
      EQT Private Equity Acquires SPT Labtech from Battery Ventures
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Highlights from Paris Packaging Week
      Walgreens Boots Alliance Decides Not to Sell Boots and No7 Beauty Company Businesses
      WWP Beauty Unveils New Packaging Collections in Collaboration with Eastman
      Happi

      Latest Breaking News From Happi

      Evonik Holds Groundbreaking Ceremony for Commercial Rhamnolipid Production Facility
      CHT USA Hosts Groundbreaking Ceremony for $20 Million US Headquarters Expansion
      Azelis Expands Global Flavors & Fragrances Platform with Acquisition in India
      Ink World

      Latest Breaking News From Ink World

      Temporary Content Title
      Amcor Lift-Off Initiative Shortlists Start-ups for Seed Funding
      Barentz Highlights Lincoln MFG’s New ISO 9001:2015 Certification
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Sibress launches FADS3D flexo plate measuring device
      Mike Brown appointed VP for Davis-Standard’s Canadian operations
      Constantia Flexibles introduces chemical resistant recycle-ready laminate
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Suominen Launches Hydraspun Reserve
      Richard Knowlson Receives Lifetime Technical Achievement Award
      Skylark Launches Thicker Label Closure Technology in North American
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Tecomet Appoints Bill Dow as President & CEO
      Medacta, InSilicoTrials Partner on Orthopedic Device Development
      Researchers Develop Microfluidic Sensors to Improve Implant Survival Rates
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Avery Dennison Launches New Dual-Frequency RFID Inlay
      Avery Dennison Highlights New Approach to Apparel with ADX Lab
      trinamiX Face Authentication Protects Users from Fraud Attacks During Mobile Payments

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login